Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Investopedia

01-13

Key Takeaways

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.
The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.
Biogen already owns a 10.2% stake in Sage.

Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.

The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.

The biopharmaceutical firm said its board "will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders."

Biogen Owns 10.2% Stake in Sage

According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.

The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.

Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.

TradingView

Do you have a news tip for Investopedia reporters? Please email us at

tips@investopedia.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503589820"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503589820\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503589820?lang=zh_TW&edition=fundamental","thumbnail":"https://www.investopedia.com/thmb/q9_MAdxlQyU1CGKdgYB_VgASepU=/2872x1915/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1742678123-25d92008a8844f64a3b09d5739a8612f.jpg","is_english":true,"pubTime":"2025-01-13 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503589820","market":"sg","top_or_hot":-1,"title":"Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid","media":"Investopedia","content":"<html><body><div><div><div><h3>Key Takeaways</h3>\n<div><ul><li><a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.</li><li>The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.</li><li>Biogen already owns a 10.2% stake in Sage.</li></ul></div></div></div>\n<p> Sage <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.<span></span>\n</p>\n<div></div>\n<p> The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.\n</p>\n<div></div>\n<p> The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\"\n</p>\n<div></div>\n<span></span><h2> <span> Biogen Owns 10.2% Stake in Sage </span> </h2>\n<p> According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.<span></span>\n</p>\n<div></div>\n<p> The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.<span></span>\n</p>\n<div></div>\n<p> Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.\n</p>\n<div></div>\n<figure> <div>\n<div>\n<img height=\"811\" width=\"1542\"/>\n<noscript>\n<img height=\"811\" sizes=\"750px\" src=\"https://www.investopedia.com/thmb/JT4Byri3xjsY5Go2e7dJMU06Ef8=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/SAGE_2025-01-13_09-34-27-5507f125057c4736a6c73d8fdd78e7bc.png\" srcset=\"https://www.investopedia.com/thmb/Xi7IbI4pjCDujuyIgaRQd5zBzyw=/750x0/filters:no_upscale():max_bytes(150000):strip_icc()/SAGE_2025-01-13_09-34-27-5507f125057c4736a6c73d8fdd78e7bc.png 750w\" width=\"1542\"/>\n</noscript>\n</div> </div>\n<figcaption> <span><p>TradingView</p></span>\n</figcaption></figure>\n<div><div>Do you have a news tip for Investopedia reporters? Please email us at</div>\n<span>tips@investopedia.com</span></div></div></body></html>","source":"investopedia_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investopedia</strong><span class=\"h-time small\">2025-01-13 22:51</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div><div><div><h3>Key Takeaways</h3>\n<div><ul><li><a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.</li><li>The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.</li><li>Biogen already owns a 10.2% stake in Sage.</li></ul></div></div></div>\n<p> Sage <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.<span></span>\n</p>\n<div></div>\n<p> The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.\n</p>\n<div></div>\n<p> The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\"\n</p>\n<div></div>\n<span></span><h2> <span> Biogen Owns 10.2% Stake in Sage </span> </h2>\n<p> According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.<span></span>\n</p>\n<div></div>\n<p> The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.<span></span>\n</p>\n<div></div>\n<p> Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.\n</p>\n<div></div>\n<figure> <div>\n<div>\n<img height=\"811\" width=\"1542\"/>\n<noscript>\n<img height=\"811\" sizes=\"750px\" src=\"https://www.investopedia.com/thmb/JT4Byri3xjsY5Go2e7dJMU06Ef8=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/SAGE_2025-01-13_09-34-27-5507f125057c4736a6c73d8fdd78e7bc.png\" srcset=\"https://www.investopedia.com/thmb/Xi7IbI4pjCDujuyIgaRQd5zBzyw=/750x0/filters:no_upscale():max_bytes(150000):strip_icc()/SAGE_2025-01-13_09-34-27-5507f125057c4736a6c73d8fdd78e7bc.png 750w\" width=\"1542\"/>\n</noscript>\n</div> </div>\n<figcaption> <span><p>TradingView</p></span>\n</figcaption></figure>\n<div><div>Do you have a news tip for Investopedia reporters? Please email us at</div>\n<span>tips@investopedia.com</span></div></div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.investopedia.com/sage-therapeutics-stock-soars-as-biogen-makes-unsolicited-takeover-bid-8773323\">Investopedia</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.investopedia.com/sage-therapeutics-stock-soars-as-biogen-makes-unsolicited-takeover-bid-8773323","article_id":"2503589820","we_media_id":null,"thumbnails":["https://www.investopedia.com/thmb/q9_MAdxlQyU1CGKdgYB_VgASepU=/2872x1915/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1742678123-25d92008a8844f64a3b09d5739a8612f.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503589820","pubTimestamp":1736779881,"columns":[],"sourceInfo":{"source_id":"investopedia_highlight","name":"Investopedia"},"weMediaInfo":null,"summary":"Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.Biogen already owns a 10.2% stake in Sage.Sage Therapeutics  shares soared nearly 40% Monday on news Biogen  is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\". According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1","collect":0,"end_time":0,"defaultTopTitle":"investopedia.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Biogen主动提出收购要约，Sage Therapeutics股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"SAGE":1},"content_text":"Key Takeaways\nSage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.Biogen already owns a 10.2% stake in Sage.\n Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.\n\n\n The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.\n\n\n The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\"\n\n\n  Biogen Owns 10.2% Stake in Sage  \n According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.\n\n\n The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.\n\n\n Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.\n\n\n \n\n\n\n\n\n \n TradingView\n\nDo you have a news tip for Investopedia reporters? Please email us at\ntips@investopedia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}